20/20 Biolabs is trading at $0.44, up 7.94%, with no confirmed company-specific catalyst identified. - No company-specific announcement explaining the September 30 move surfaced. Latest identified news was a September 29 announcement of an October 7 investor webinar on the FDA panel’s favorable Galleri vote and OneTest franchise; it is not confirmed as today’s catalyst. - Supplied market context shows Nasdaq up 0.57%, which may be contributing; no direct link to the stock’s rise is established.